Abstract
Sirtuins (SIRTs) are nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylases, which regulate important biological processes ranging from apoptosis, age-associated pathophysiologies, adipocyte and muscle differentiation, and energy expenditure to gluconeogenesis. Very recently, sirtuin 5 (SIRT5) has received considerable attention due to that it was found to have weak deacetylase activity but strong desuccinylase, demalonylase and deglutarylase activities, and it was also found to be associated with several human diseases such as cancer, Alzheimer’s disease, and Parkinson’s disease. In this review, we for the first time summarized the structure characteristics, known peptide and smallmolecule inhibitors of SIRT5, extracted some clues from current available information and introduced some feasible, practical in silico methods, which might be useful in further efforts to develop new SIRT5 inhibitors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bell, E.L., and Guarente, L. (2011). The SirT3 divining rod points to oxidative stress. Mol Cell 42, 561–568.
Davenport, A.M., Huber, F.M., and Hoelz, A. (2014). Structural and functional analysis of human SIRT1. J Mol Biol 426, 526–541.
De Graaf, C., Kooistra, A.J., Vischer, H.F., Katritch, V., Kuijer, M., Shiroishi, M., Iwata, S., Shimamura, T., Stevens, R.C., De Esch, I.J.P., and Leurs, R. (2011). Crystal structure-based virtual screening for fragment-like ligands of the human histamine H1 receptor. J Med Chem 54, 8195–8206.
Donmez, G., and Outeiro, T.F. (2013). SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 5, 344–352.
Du, J., Zhou, Y., Su, X., Yu, J.J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J.H., Choi, B.H., He, B., Chen, W., Zhang, S., Cerione, R.A., Auwerx, J., Hao, Q., and Lin, H. (2011). Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334, 806–809.
Ekins, S., Mestres, J., and Testa, B. (2007). In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 152, 9–20.
Gertz, M., and Steegborn, C. (2010). Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia. Biochim Biophys Acta 1804, 1658–1665.
Glorioso, C., Oh, S., Douillard, G.G., and Sibille, E. (2011). Brain molecular aging, promotion of neurological disease and modulation by sirtuin5 longevity gene polymorphism. Neurobiol Dis 41, 279–290.
He, B., Du, J., and Lin, H. (2012). Thiosuccinyl peptides as Sirt5-specific inhibitors. J Am Chem Soc 134, 1922–1925.
Hirschey, M.D. (2011). Old enzymes, new tricks: sirtuins are NAD+-dependent de-acylases. Cell Metab 14, 718–719.
Jin, L., Wei, W., Jiang, Y., Peng, H., Cai, J., Mao, C., Dai, H., Choy, W., Bemis, J.E., Jirousek, M.R., Milne, J.C., Westphal, C.H., and Perni, R.B. (2009). Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J Biol Chem 284, 24394–24405.
Jing, H., and Lin, H. (2015). Sirtuins in epigenetic regulation. Chem Rev 115, 2350–2375.
Kumar, S., and Lombard, D.B. (2015). Mitochondrial sirtuins and their relationships with metabolic disease and cancer. Antioxid Redox Signal 22, 1060–1077.
Lai, C.C., Lin, P.M., Lin, S.F., Hsu, C.H., Lin, H.C., Hu, M.L., Hsu, C.M., and Yang, M.Y. (2013). Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumor Biol 34, 1847–1854.
Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., Wu, X., Liu, L., Yang, C., Shi, J., He, X., Liu, J., Qu, Y., Guo, F., Zhao, J., Xu, W., and Zhao, S. (2015a). NADP+-IDH mutations promote hypersuccinylation that impairs mitochondria respiration and induces apoptosis resistance. Mol Cell 60, 661–675.
Li, G.B., Ji, S., Yang, L.L., Zhang, R.J., Chen, K., Zhong, L., Ma, S., and Yang, S.Y. (2015b). LEADOPT: an automatic tool for structurebased lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors. Eur J Med Chem 93, 523–538.
Li, G.B., Yang, L.L., Feng, S., Zhou, J.P., Huang, Q., Xie, H.Z., Li, L.L., and Yang, S.Y. (2011). Discovery of novel mGluR1 antagonists: a multistep virtual screening approach based on an SVM model and a pharmacophore hypothesis significantly increases the hit rate and enrichment factor. Bioorg Med Chem Lett 21, 1736–1740.
Li, G.B., Yang, L.L., Wang, W.J., Li, L.L., and Yang, S.Y. (2013). ID-score: a new empirical scoring function based on a comprehensive set of descriptors related to protein-ligand interactions. J Chem Inf Model 53, 592–600.
Li, G.B., Yang, L.L., Yuan, Y., Zou, J., Cao, Y., Yang, S.Y., Xiang, R., and Xiang, M. (2015c). Virtual screening in small molecule discovery for epigenetic targets. Methods 71, 158–166.
Lin, Z.F., Xu, H.B., Wang, J.Y., Lin, Q., Ruan, Z., Liu, F.B., Jin, W., Huang, H.H., and Chen, X. (2013). SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem Biophys Res Commun 441, 191–195.
Liu, L., Peritore, C., Ginsberg, J., Shih, J., Arun, S., and Donmez, G. (2015). Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson’s disease. Behav Brain Res 281, 215–221.
Lu, W., Zuo, Y., Feng, Y., and Zhang, M. (2014). SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. Tumor Biol 35, 10699–10705.
Lutz, M.I., Milenkovic, I., Regelsberger, G., and Kovacs, G.G. (2014). Distinct patterns of sirtuin expression during progression of Alzheimer’s disease. Neuromol Med 16, 405–414.
Maurer, B., Rumpf, T., Scharfe, M., Stolfa, D.A., Schmitt, M.L., He, W., Verdin, E., Sippl, W., and Jung, M. (2012). Inhibitors of the NAD+ -dependent protein desuccinylase and demalonylase Sirt5. ACS Med Chem Lett 3, 1050–1053.
Mauser, H., and Guba, W. (2008). Recent developments in de novo design and scaffold hopping. Curr Opin Drug Discov Devel 11, 365–374..
Mellini, P., Valente, S., and Mai, A. (2015). Sirtuin modulators: an updated patent review (2012–2014). Expert Opin Ther Patents 25, 5–15.
Moniot, S., Schutkowski, M., and Steegborn, C. (2013). Crystal structure analysis of human Sirt2 and its ADP-ribose complex. J Struct Biol 182, 136–143.
Muthas, D., Sabnis, Y.A., Lundborg, M., and Karlén, A. (2008). Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. J Mol Graph Model 26, 1237–1251.
Nakagawa, T., Lomb, D.J., Haigis, M.C., and Guarente, L. (2009). SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137, 560–570.
Network, A.R. (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615.
Nishida, Y., Rardin, M.J., Carrico, C., He, W., Sahu, A.K., Gut, P., Najjar, R., Fitch, M., Hellerstein, M., Gibson, B.W., and Verdin, E. (2015). SIRT5 regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target. Mol Cell 59, 321–332.
Pan, P.W., Feldman, J.L., Devries, M.K., Dong, A., Edwards, A.M., and Denu, J.M. (2011). Structure and biochemical functions of SIRT6. J Biol Chem 286, 14575–14587.
Parihar, P., Solanki, I., Mansuri, M.L., and Parihar, M.S. (2015). Mitochondrial sirtuins: emerging roles in metabolic regulations, energy homeostasis and diseases. Exp Gerontol 61, 130–141.
Park, J., Chen, Y., Tishkoff, D.X., Peng, C., Tan, M., Dai, L., Xie, Z., Zhang, Y., Zwaans, B.M.M., Skinner, M.E., Lombard, D.B., and Zhao, Y. (2013). SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell 50, 919–930.
Polletta, L., Vernucci, E., Carnevale, I., Arcangeli, T., Rotili, D., Palmerio, S., Steegborn, C., Nowak, T., Schutkowski, M., Pellegrini, L., Sansone, L., Villanova, L., Runci, A., Pucci, B., Morgante, E., Fini, M., Mai, A., Russo, M.A., and Tafani, M. (2015). SIRT5 regulation of ammonia-induced autophagy and mitophagy. Autophagy 11, 253–270.
Rardin, M.J., He, W., Nishida, Y., Newman, J.C., Carrico, C., Danielson, S.R., Guo, A., Gut, P., Sahu, A.K., Li, B., Uppala, R., Fitch, M., Riiff, T., Zhu, L., Zhou, J., Mulhern, D., Stevens, R.D., Ilkayeva, O.R., Newgard, C.B., Jacobson, M.P., Hellerstein, M., Goetzman, E.S., Gibson, B.W., and Verdin, E. (2013). SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab 18, 920–933.
Ren, J.X., Li, L.L., Zheng, R.L., Xie, H.Z., Cao, Z.X., Feng, S., Pan, Y.L., Chen, X., Wei, Y.Q., and Yang, S.Y. (2011). Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking. J Chem Inf Model 51, 1364–1375.
Roessler, C., Nowak, T., Pannek, M., Gertz, M., Nguyen, G.T.T., Scharfe, M., Born, I., Sippl, W., Steegborn, C., and Schutkowski, M. (2014). Chemical probing of the human sirtuin 5 active site reveals its substrate acyl specificity and peptide-based inhibitors. Angew Chem Int Engl 53, 10728–10732.
Roessler, C., Tüting, C., Meleshin, M., Steegborn, C., and Schutkowski, M. (2015). A novel continuous assay for the deacylase sirtuin 5 and other deacetylases. J Med Chem 58, 7217–7223.
Rumpf, T., Schiedel, M., Karaman, B., Roessler, C., North, B.J., Lehotzky, A., Oláh, J., Ladwein, K.I., Schmidtkunz, K., Gajer, M., Pannek, M., Steegborn, C., Sinclair, D.A., Gerhardt, S., Ovádi, J., Schutkowski, M., Sippl, W., Einsle, O., and Jung, M. (2015). Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat Commun 6, 6263.
Schneider, G., and Fechner, U. (2005). Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 4, 649–663.
Schuetz, A., Min, J., Antoshenko, T., Wang, C.L., Allali-Hassani, A., Dong, A., Loppnau, P., Vedadi, M., Bochkarev, A., Sternglanz, R., and Plotnikov, A.N. (2007). Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 15, 377–389.
Suenkel, B., Fischer, F., and Steegborn, C. (2013). Inhibition of the human deacylase Sirtuin 5 by the indole GW5074. Bioorg Med Chem Lett 23, 143–146.
Suri, C., and Naik, P.K. (2015). Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to g-tubulin dimer. SAR QSAR Environ Res 26, 507–519.
Szczepankiewicz, B.G., Dai, H., Koppetsch, K.J., Qian, D., Jiang, F., Mao, C., and Perni, R.B. (2012). Synthesis of carba-NAD and the structures of its ternary complexes with SIRT3 and SIRT5. J Org Chem 77, 7319–7329.
Talamas, F.X., Ao-Ieong, G., Brameld, K.A., Chin, E., De Vicente, J., Dunn, J.P., Ghate, M., Giannetti, A.M., Harris, S.F., Labadie, S.S., Leveque, V., Li, J., Lui, A.S.T., McCaleb, K.L., Nájera, I., Schoenfeld, R.C., Wang, B., and Wong, A. (2013). De novo fragment design: a medicinal chemistry approach to fragment-based lead generation. J Med Chem 56, 3115–3119.
Tan, M., Peng, C., Anderson, K.A., Chhoy, P., Xie, Z., Dai, L., Park, J., Chen, Y., Huang, H., Zhang, Y., Ro, J., Wagner, G.R., Green, M.F., Madsen, A.S., Schmiesing, J., Peterson, B.S., Xu, G., Ilkayeva, O.R., Muehlbauer, M.J., Braulke, T., Mü hlhausen, C., Backos, D.S., Olsen, C.A., McGuire, P.J., Pletcher, S.D., Lombard, D.B., Hirschey, M.D., and Zhao, Y. (2014). Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab 19, 605–617.
Yang, L.L., Li, G.B., Yan, H.X., Sun, Q.Z., Ma, S., Ji, P., Wang, Z.R., Feng, S., Zou, J., and Yang, S.Y. (2012). Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. Eur J Med Chem 56, 30–38.
Yang, S.Y. (2010). Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15, 444–450.
Yang, X., Liu, B.Y., Zhu, W.G., and Luo, J.Y. (2015). SIRT5, functions in cellular metabolism with a multiple enzymatic activities. Sci China Life Sci 58, 912–914.
Zang, W., Hao, Y., Wang, Z., and Zheng, W. (2015). Novel thiourea-based sirtuin inhibitory warheads. Bioorg Med Chem Lett 25, 3319–3324.
Zhang, Y., Bharathi, S.S., Rardin, M.J., Uppala, R., Verdin, E., Gibson, B.W., Goetzman, E.S., and Makishima, M. (2015). SIRT3 and SIRT5 regulate the enzyme activity and cardiolipin binding of very long-chain Acyl-CoA dehydrogenase. PLoS ONE 10, e0122297.
Zhou, Y., Zhang, H., He, B., Du, J., Lin, H., Cerione, R.A., and Hao, Q. (2012). The bicyclic intermediate structure provides insights into the desuccinylation mechanism of human sirtuin 5 (SIRT5). J Biol Chem 287, 28307–28314.
Acknowledgements
This work was supported by the Chun hui of Ministry of Education Project (Z2015120), the National Natural Science Foundation of China (81502989), and the China Postdoctoral Science Foundation Funded Project (2015M570789).
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at springerlink.bibliotecabuap.elogim.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Yang, L., Ma, X., He, Y. et al. Sirtuin 5: a review of structure, known inhibitors and clues for developing new inhibitors. Sci. China Life Sci. 60, 249–256 (2017). https://doi.org/10.1007/s11427-016-0060-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-016-0060-7